AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
0.000 (-0.07%)
After Hours: 0.850 +0.140 (19.80%)
Dec 17, 7:03PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.69 - 0.72
52 week 0.61 - 2.07
Open 0.72
Vol / Avg. 0.00/236,123.00
Mkt cap 37.93M
P/E     -
Div/yield     -
EPS -1.08
Shares 52.26M
Beta     -
Inst. own 40%
Nov 24, 2014
Aveo Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1653.61% -8277.57%
Operating margin -1615.01% -8035.89%
EBITD margin - -7121.96%
Return on average assets -60.80% -60.50%
Return on average equity -142.57% -113.33%
Employees 71 -
CDP Score - -


United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, is a biopharmaceutical company. The Company is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors, and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite.

Officers and directors

Henri A. Termeer Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Tuan Ha-Ngoc President, Chief Executive Officer, Principal Financial Officer, Director
Age: 62
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel
Age: 42
Bio & Compensation  - Reuters
Jeno Gyuris Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Michael P. Bailey Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Robert C. Young M.D Independent Director
Age: 74
Bio & Compensation  - Reuters